Scholarlink

<p>This study investigates how institutional investors enhance pharmaceutical innovation in China via industry integration (2007–2022). Findings reveal that interconnected firms with institutional ownership exhibit stronger innovation, particularly in patents, driven by channels of agenda control, knowledge transfer, and portfolio risk diversification. Foreign institutional investors significantly boost innovation through global networks and technology transfer. Shared governance structures, including ownership ties and board interlocks, facilitate resource integration and collaborative innovation in regulated markets. The research underscores institutional investors’ dual role as capital providers and innovation catalysts, offering policy insights for leveraging cross-firm governance mechanisms to advance pharmaceutical R&amp;D competitiveness in emerging economies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effects of industry integration on pharmaceutical firm innovation: institutional investors’ perspective

  • 期刊论文

  • 发表日期：

    2026年6月15日

查看全文
  • Lu Yao,
  • Ronghan Xie,
  • Mengde Liu

摘要

This study investigates how institutional investors enhance pharmaceutical innovation in China via industry integration (2007–2022). Findings reveal that interconnected firms with institutional ownership exhibit stronger innovation, particularly in patents, driven by channels of agenda control, knowledge transfer, and portfolio risk diversification. Foreign institutional investors significantly boost innovation through global networks and technology transfer. Shared governance structures, including ownership ties and board interlocks, facilitate resource integration and collaborative innovation in regulated markets. The research underscores institutional investors’ dual role as capital providers and innovation catalysts, offering policy insights for leveraging cross-firm governance mechanisms to advance pharmaceutical R&D competitiveness in emerging economies.